A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.

Trial Profile

A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms MUSIC
  • Sponsors UCB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2012 Results have been published in Gut.
    • 17 Oct 2010 Health-related quality-of-life data were presented in an absract at the 75th Annual Scientific Meeting of the American College of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top